Regentis Biomaterials Ltd. has been granted a new U.S. patent for its off-the-shelf regenerative cartilage repair product, GelrinC. The patent covers a ready-to-use liquid formulation of GelrinC and improved production processes that avoid the use of organic solvents. This innovation aims to simplify procedures for surgeons, enabling a cartilage repair process that takes approximately 10 minutes. The patent provides protection through 2038, with the potential for further extensions tied to future developments. GelrinC is currently undergoing a pivotal FDA trial and has received regulatory approval in the EU.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regentis Biomaterials Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-123065), on December 18, 2025, and is solely responsible for the information contained therein.